NCT02354508 · MORE INFO

Limitations, agreements, and source contact

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues · Source last updated 2019-12-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: The study is a single-arm study to evaluate the safety \& efficacy of pasireotide LAR in patients with inadequately controlled acromegaly who were previously on somatostatin analogues: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.

point Of Contact

Complete source fields

certain Agreement

other Details: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: The study is a single-arm study to evaluate the safety \& efficacy of pasireotide LAR in patients with inadequately controlled acromegaly who were previously on somatostatin analogues: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice